Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVO | Novo Nordisk A/S

Index- P/E21.57 EPS (ttm)4.23 Insider Own26.40% Shs Outstand8.98B Perf Week-4.11%
Market Cap323.57B Forward P/E12.17 EPS next Y7.50 Insider Trans0.00% Shs Float5.51B Perf Month-3.91%
Income9.60B PEG7.70 EPS next Q1.94 Inst Own8.40% Short Float / Ratio0.07% / 1.10 Perf Quarter14.79%
Sales28.73B P/S11.26 EPS this Y17.80% Inst Trans-5.12% Short Interest3.89M Perf Half Y22.08%
Book/sh2.88 P/B31.70 EPS next Y12.60% ROA26.50% Target Price77.61 Perf Year84.04%
Cash/sh1.47 P/C62.28 EPS next 5Y2.80% ROE81.40% 52W Range47.51 - 100.88 Perf YTD34.92%
Dividend2.06 P/FCF- EPS past 5Y-4.50% ROI56.10% 52W High-9.50% Beta0.45
Dividend %2.25% Quick Ratio0.70 Sales past 5Y9.60% Gross Margin84.40% 52W Low92.17% ATR2.24
Employees59337 Current Ratio0.90 Sales Q/Q31.60% Oper. Margin42.80% RSI (14)44.57 Volatility2.37% 1.88%
OptionableYes Debt/Eq0.28 EPS Q/Q47.50% Profit Margin33.40% Rel Volume0.83 Prev Close91.29
ShortableYes LT Debt/Eq0.21 EarningsAug 10 BMO Payout33.02% Avg Volume3.54M Price91.30
Recom1.50 SMA20-3.96% SMA502.54% SMA20016.22% Volume2,944,512 Change0.01%
Date Action Analyst Rating Change Price Target Change
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Apr-25-22Upgrade Cowen Market Perform → Outperform $130
Apr-12-22Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22Upgrade Deutsche Bank Hold → Buy
Jan-25-22Downgrade Liberum Hold → Sell
Sep-22-23 03:23PM
12:09PM
09:53AM
04:47AM
Sep-21-23 08:27PM
04:15PM Loading…
04:15PM
03:56PM
12:26PM
11:19AM
09:34AM
09:16AM
08:00AM
01:00AM
Sep-20-23 11:39PM
11:27PM
05:50PM Loading…
05:50PM
05:08PM
02:58PM
10:23AM
09:51AM
09:30AM
06:00AM
05:46AM
05:08AM
03:38AM
02:00AM
Sep-18-23 04:06PM
11:50AM
08:02AM
07:36AM
07:36AM Loading…
07:36AM
05:21AM
05:20AM
Sep-16-23 08:38AM
07:15AM
07:05AM
03:30AM
Sep-15-23 04:42PM
09:33AM
07:45AM
05:49AM
Sep-14-23 07:00PM
05:50PM
11:28AM
10:15AM
09:30AM
05:52AM
05:00AM
Sep-13-23 02:34PM
11:33AM
07:30AM
05:32AM
01:30AM
Sep-12-23 12:21PM
11:46AM
05:06AM
05:05AM
Sep-11-23 12:32PM
08:01AM
Sep-10-23 06:12AM
Sep-09-23 03:59PM
09:15AM
Sep-08-23 05:50PM
12:47PM
09:45AM
08:23AM
08:19AM
Sep-07-23 08:37PM
06:03PM
11:43AM
11:39AM
10:07AM
10:00AM
09:29AM
Sep-06-23 01:41PM
12:41PM
Sep-05-23 01:52PM
10:17AM
09:02AM
08:06AM
07:58AM
07:47AM
06:50AM
05:43AM
04:53AM
04:40AM
01:00AM
01:00AM
01:00AM
12:41AM
Sep-04-23 01:38PM
01:34PM
01:34PM
01:34PM
08:12AM
08:01AM
06:14AM
05:29AM
03:30AM
03:02AM
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.